Silo Pharma, Inc. (SILO)

NASDAQ: SILO · IEX Real-Time Price · USD
3.49
-0.06 (-1.69%)
Dec 6, 2022 2:56 PM EST - Market open
-1.69%
Market Cap 11.14M
Revenue (ttm) 72,102
Net Income (ttm) -3.33M
Shares Out 2.00M
EPS (ttm) 3.27
PE Ratio 1.07
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,174
Open 3.55
Previous Close 3.55
Day's Range 3.34 - 3.63
52-Week Range 0.17 - 12.45
Beta -0.84
Analysts n/a
Price Target n/a
Earnings Date n/a

About SILO

Silo Pharma. Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. It is developing solutions to address various underserved conditions. The company seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the benefits they may have in certain cases involving depression, mental health issues, and neurological disorders. The company focu... [Read more]

Industry Biotechnology
Founded 2010
Employees 2
Stock Exchange NASDAQ
Ticker Symbol SILO
Full Company Profile

Financial Performance

Financial Statements

News

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics wi...

ENGLEWOOD CLIFFS, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) --   Silo Pharma, Inc. ( Nasdaq: SILO ) (“the Company”) , a developmental stage biopharmaceutical company focused on merging traditional therapeutics...

5 days ago - GlobeNewsWire

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Initial data from study expected in first quarter 2023

2 weeks ago - GlobeNewsWire

7 Millionaire-Maker Stocks You Will Regret Not Buying This Year

Although the concept of millionaire-maker stocks will always attract attention, at the moment, investors must realize the rules have changed. Fundamentally, the Federal Reserve remains committed to atta...

Other symbols: DSWLEGYFSISPRSUMC
2 weeks ago - InvestorPlace

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...

3 weeks ago - GlobeNewsWire

Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference

ENGLEWOOD CLIFFS, NJ, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...

1 month ago - GlobeNewsWire

What Is Going on With Silo Pharma (SILO) Stock Today?

Silo Pharma (NASDAQ: SILO ) stock is falling on Thursday despite the company releasing positive data from a pre-clinical study. This data covers the use of SPC-14 as a therapeutic treatment for Alzheime...

1 month ago - InvestorPlace

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer's Disease in Pre-Clinical Study

Dosing study of SPC-14 demonstrates efficacy for increasing memory function Dosing study of SPC-14 demonstrates efficacy for increasing memory function

1 month ago - GlobeNewsWire

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Studies of SP-26, the company's proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain

1 month ago - GlobeNewsWire

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Presentation to feature Company's novel therapeutic candidates under development in collaboration with leading academic institutions

2 months ago - GlobeNewsWire

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine

2 months ago - GlobeNewsWire

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of ...

ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic re...

2 months ago - GlobeNewsWire

Can Silo Pharma (SILO) Stock Be a Hot Nasdaq Debut?

In today's turbulent market, what was once green is now red for many companies across all major indices. That said, among today's bigger losers is Silo Pharma (NASDAQ: SILO ), as this early-stage biotec...

2 months ago - InvestorPlace

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol “SILO” Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol...

2 months ago - GlobeNewsWire

Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

ENGLEWOOD CLIFFS, NJ , Sept. 15, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics wit...

2 months ago - GlobeNewsWire

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system

4 months ago - GlobeNewsWire

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc  . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive endp...

4 months ago - GlobeNewsWire

Silo Pharma Expands License Agreement and Patent Portfolio

Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes

5 months ago - GlobeNewsWire

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study

Study is examining effects of Psilocybin on Inflammatory Markers ENGLEWOOD CLIFFS, N.J., May 19, 2022 (GLOBE NEWSWIRE) --  Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company...

6 months ago - GlobeNewsWire

Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

SPU-21 has shown Anti-arthritic activity for therapeutic use in preclinical studies. SPU-21 has shown Anti-arthritic activity for therapeutic use in preclinical studies.

7 months ago - GlobeNewsWire

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

IND Enabling Study to prepare Silo Pharma Homing Peptides for Clinic IND Enabling Study to prepare Silo Pharma Homing Peptides for Clinic

8 months ago - GlobeNewsWire

IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.

NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedel...

8 months ago - GlobeNewsWire

Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation

10 months ago - GlobeNewsWire

Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the en...

11 months ago - GlobeNewsWire

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

U.S. Patent and Trademark Office issued US Patent No. 11,174,287 investigation, detection, treatment or prevention of neuroinflammation U.S. Patent and Trademark Office issued US Patent No. 11,174,287 i...

1 year ago - GlobeNewsWire

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced ...

1 year ago - GlobeNewsWire